Background While the association between renal impairment and cardiovascular disease (CVD) is well
Introduction
The association between impaired renal function and cardiovascular disease (CVD) is well established in the general population, in particular for severe levels of renal impairment [1] [2] [3] [4] [5] [6] . As such more than 50% of all deaths in individuals with end-stage renal disease are related to a CVD event [7] . In contrast, most prior studies that have investigated the relation between renal impairment and CVD in HIV-positive individuals have been small, have used relatively broad definitions of CVD, or have focused on single measures of renal function which are subjected to random variation and the transient effects of acute illness [8] [9] [10] [11] [12] [13] . The influence of a more sustained impairment of estimated glomerular filtration rate (eGFR) on well-defined CVD events in HIV-positive individuals is less clear.
Renal impairment is projected to become more prevalent among HIV-positive individuals in future years due to ageing and an accumulating burden of comorbidities and lifestyle related risk factors.
CVD is furthermore now one of the leading causes of non-AIDS death in HIV-positive individuals [14] . A better understanding of the rates of CVD among HIV-positives individuals with renal impairment is therefore warranted to assist identification of those at highest risk with a need for intensified monitoring and initiation of preventive measures [15] The relationship between renal impairment and CVD is complex and may be mediated through a variety of different pathways [3, 6, 14] . These include accelerated coronary-and cerebrovascular atherosclerosis which may be mediated in part by increased inflammation and oxidative stress, atrial fibrillation and ventricular hypertrophy, which are common at severe levels of renal impairment and may, similar to electrolyte abnormalities, promote dysrhythmias resulting in stroke or sudden cardiac death [3, [15] [16] [17] [18] [19] [20] .
Finally renal impairment and CVD are known to share a common underlying risk factor profile which include hypertension, diabetes, dyslipidemia, smoking, injecting drug use, obesity, on-going inflammation and black African origin [20, 21] . CVD, renal impairment, and many of the underlying shared individual risk factors, are more prevalent among HIV-positive individuals than in the general population, hence the association A c c e p t e d M a n u s c r i p t 5 death according to the WHO MONICA Dundee score [24] , and no evidence of other non-atherosclerotic or noncardiovascular causes of death. All sudden cardiac deaths in the D:A:D study are reviewed by an external cardiologist.
Statistical methods

D:
A:D Study participants with >2 eGFR measurements after 1/2/2004 (baseline for initiation of systematic creatinine collection) were included and followed until the earliest of first CVD event, death, six months after last visit or 1/2/2015. Persons with less than three months follow-up from the first to last eGFR were excluded. The Cockcroft-Gault equation [25] , standardized for body surface area [26] , was used to estimate creatinine clearance, a surrogate for eGFR in this analysis [27, 28] . As several cohorts participating in D:A:D are prohibited from collecting ethnicity information, the Cockcroft-Gault equation was used rather than an equation including ethnicity. Where eGFR measurements were carried out more frequently than every 28 days, the median value was used and assigned to the median date. Confirmed baseline and time-updated (current) eGFR levels were defined using two consecutive eGFR measurements, regardless of time between measurements (per definition minimum 28 days). The confirmed baseline and current eGFR values were subsequently allocated to the following eGFR strata: >90, >60-<90, >30-<60 and <30 ml/min/1.73m 2 . Where two consecutive eGFR values (<15% of all values) did not fall within the same eGFR strata, the mean of two eGFR values carried forward was used to assign an eGFR category.
Individuals with a prior CVD event were included, but only the first CVD event experienced during prospective follow-up after baseline was included as an event. Individuals could however experience two or more different types of CVD event on the same date.
Incidence rates were calculated per 1000 person years of follow-up (PYFU). Kaplan-Meier estimation was used to investigate time to CVD, stratified according to confirmed baseline eGFR levels (eGFR>90, <90->60, <60->30, <30 ml/min/1.73m high risk group (score >5) [29] . A final analysis investigated the association between current nadir eGFR and the percentage of follow-up time spent with eGFR<60 ml/min/1.73m 2 and CVD respectively. Table 1 . While 41.6% were smokers, 4.0% had diabetes, 8.9% had hypertension and 0.7% had experienced a prior CVD event. At baseline the median estimated five year risk of CKD was low overall (-1 (IQR -3 to4) corresponding to 0.3%) and medium (4 (IQR1to 9) corresponding to 2.1%) in those developing a CVD event, Table 1 . 558 persons were excluded from analysis due to missing CD4 counts or viral load at baseline, or because of insufficient follow-up. Excluded persons were more likely to be young, of Caucasian origin, cART-naïve, HCV-positive, have no family history of CVD and have experienced a prior AIDS event.
Age and eGFR level
Among individuals younger than 40 years 87.0% (n=13,660) had a normal (confirmed eGFR>90 ml/min/1.73m
2 ) baseline eGFR, and only 0.04% (n=7) had advanced renal impairment (confirmed baseline eGFR<30 ml/min/1.73m
2 ). In contrast, among individuals older than 60 years, only 15.8% (n=321) had confirmed baseline eGFR>90ml/min/1.73m 2 and 0.8% (n=17) confirmed baseline eGFR<30 ml/min/1.73m 2 .
CVD events
Over a median follow-up time of 8.0 years (IQR, 5. (p=0.018). When excluding the coronary bypass events there was no statistically significant differences in confirmed eGFR levels prior to a CVD event (p=0.068). Likewise, when comparing those with an invasive cardiovascular procedures (coronary angioplasty, carotid endarterectomy or coronary bypass) to those with a myocardial infarction and/or stroke there was no statistical significant difference (p=0.55), Figure 1 .
Confirmed baseline eGFR levels and incident CVD
We observed a clear inverse relationship between confirmed eGFR levels at baseline and incident CVD with 
Confirmed current eGFR level and incident CKD
There was a strong and inverse linear relationship between confirmed current eGFR and CVD in univariate analysis; incidence rate ratios (IRRs) increasing from 1.00 at eGFR>90 ml/min/1. There was no strong evidence suggesting that the observed association between confirmed current eGFR levels and CVD differed amongst the individual types of CVD events. When restricting the analysis to fatal CVD events only, all observed associations were further strengthened (data not shown). Our findings were furthermore consistent in different age groups (test for interaction, p=0.88), and after accounting for death as a possible competing risk for CVD (data not shown). The association between CVD and confirmed eGFR seen in the primary analyses was largely unchanged by fitting renal function as current nadir eGFR and as 
Confirmed current eGFR levels and number of CVD events
Individuals with higher confirmed current eGFR levels experienced two or more CVD events (at the same date) more frequently than those with lower eGFR levels (24.7% at eGFR>90 ml/min/1.73m 2 vs.4.2% at eGFR<30 ml/min/1.73m 2 , p=0.0034), most commonly a myocardial infarction and coronary angioplasty.
Furthermore, the proportion of individuals experiencing a fatal CVD event (death within 28 days following the event) was strongly related to the confirmed current eGFR level, increasing from 4.4% in individuals with a confirmed current eGFR>90 ml/min/1.73m 2 to 25.0% in individuals with a confirmed current eGFR<30 ml/min/1.73m 2 (p<0.0001).
Discussion
In this large heterogeneous cohort of HIV-positive individuals we found a strong association between centrally adjudicated CVD events and advanced levels of renal impairment (confirmed eGFR<30 ml/min/1.73m
2 ).
Almost 60% of all individuals experiencing a CVD event had eGFR<90 ml/min/1.73m 2 , based on the latest median eGFR before the event, compared to less than 40% of those without an event. We further showed that development of a CVD event was considerately faster among those with a severely impaired eGFR at baseline. Among HIV-positive individuals with confirmed baseline eGFR<30 ml/min/1.73m 2 over 20% were estimated to have developed CVD after five years.
In previous studies from D:A:D we have investigated the inverse relation between CVD events and eGFR, focusing on CVD as a risk factor of various levels of chronic renal impairment [28, 29, 31] . Interestingly, these previous data also supported a strong association between CVD and renal function which significantly diminished after accounting for other risk factors suggesting an underlying biological mechanism at least by Jules Levin on August 18, 2016 http://jid.oxfordjournals.org/
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A c c e p t e d M a n u s c r i p t 11 partly mediated by other factors. We have also previously showed an association between the use of certain antiretroviral drugs and CVD and renal impairment [28, 30, 32] . The results of this analysis are entirely consistent with these prior findings, and adjustment for the use of individual antiretroviral drugs did not have any major impact on the association between impaired eGFR and CVD. Data from this analysis points towards increasing age as the main underlying driver of the inverse relationship between eGFR and CVD, in particular at mild to moderately impaired eGFR levels [14] . At more advanced levels of renal impairment (eGFR<30 ml/min/1. In other studies of HIV-positive individuals, a smaller cross-sectional analysis in the FRAM study did not confirm an association between carotid intima-medial thickness and eGFR after accounting for older age, gender and ethnicity [13] . Likewise, a British study did not find an association between eGFR as a continuous variable and coronary heart disease, although those with eGFR<75 mL/min already had more than a 4-fold increased incidence [9] . In a recent EuroSIDA study both the follow-up time with a low eGFR and eGFR<30 ml/min/1.73m 2 were predictive of non-AIDS events including CVD, but power was limited [12] . An older large cohort study among HIV-positive US veterans showed an almost 6-fold higher association between eGFR<30 ml/min, albuminuria and CVD, although this study also included peripheral artery disease and heart failure [10] .
Our findings do not suggest that the association between declining renal function and CVD is stronger, or starts at higher eGFR levels in HIV-positive persons than in the general population, as was hypothesised based on the higher occurrence of common renal and CVD risk factors and increased immune activation [1, A c c e p t e d M a n u s c r i p t 12 4, 33, 34] . There is, however, ongoing ambiguity, in the general population, regarding the strength of the association between impaired renal function and CVD. Some studies report only on an association with CVD at advanced levels of renal impairment (eGFR<30 ml/min/1.73m
2 ) while others report of associations already at higher eGFR levels [1, 4, 5, 9, 10, 14, 33, 34] . However, the definitions of CVD differ considerately in these studies ranging from subclinical imaging-verified diagnoses of atherosclerosis to various clinical events ascertained with different levels of certainty. The differences in the incidence of common risk factors and of CVD and renal impairment may also partly explain the conflicting results. Importantly, the D:A:D study focuses on 'hard' clinical CVD events exclusively and information on non-fatal heart failure or milder forms of ischemic CVD such as angina pectoris is not collected. This methodology may explain why more severe levels of renal impairment are necessary to establish an association with CVD. Interestingly, none of the widely accepted CVD risk prediction models currently include renal impairment in the estimates [30, 32] , but the proportion of individuals with advanced renal impairment may be too limited to date.
We also found that fatal outcomes of a CVD event were more common at lower compared to higher eGFR levels, which may be related to a more severe clinical event or to the fact that those with advanced levels of renal impairment provide a more fragile phenotype with less ability to cope with CVD complications.
Likewise, fewer multiple CVD events occurred on the same date among those with lower eGFR levels. This finding may be related to the increased fatality rate at lower eGFR levelsor that those with lower eGFR levels are less likely to undergo invasive cardiovascular procedures as secondary prophylaxis, due to concerns about radiocontrast induced nephrotoxicity. Interestingly, there was no evidence of a relation between the eGFR level and type of CVD outcome i.e. a myocardial infarction did not seem to occur at different eGFR levels to other CVD events, with the exception of coronary bypass. Coronary bypass was more commonly carried out at lower eGFR levels, compared to the other CVD events, which may suggest more advanced atherosclerosis with multiple vessel disease in this population.
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The potential limitations of the analysis should be acknowledged. We may have underestimated the proportion of individuals with an impaired eGFR level as those excluded from analysis were more likely to have common renal risk factors; hence the provided relation between eGFR and CVD is of a conservative nature. Proteinuria is a potential source of unmeasured confounding as it not collected systematically in the D:A:D study, and may further have moderating effects as it is a strong independent risk factor for both CVD and CKD [35] .Furthermore, renal impairment may have developed secondary to a CVD event as part of a cardiorenal syndrome, with potentials of reverse causality. However, in this analysis eGFR impairment proceeded all prospectively investigated CVD events [36] . Finally, non-ischemic events such as cardiac arrhythmias and ventricular hypertrophy were not directly included in the CVD definition, but may have contributed more indirectly via stroke and sudden cardiac death events.
Conclusion
In a large, contemporary cohort of HIV-positive individuals we observed a strong relationship between confirmed impaired renal function and incident CVD. More than one in five of those with advanced levels of renal impairment were estimated to have developed CVD by five years, with an increasing 28-day CVD fatality rate as eGFR declined. Our findings highlight the need for an intensified monitoring for emerging CVD, in particular in older individuals with continuously low eGFR levels. Our findings also call for an increased focus on applying different renal and cardiovascular preventive measures in HIV-positive individuals. count, prior AIDS, hypertension, diabetes, confirmed eGFR strata, smoking status, dyslipidemia, prior CVD, exposure to antiretroviral drugs fitted as cumulative use (to zidovudine, didanosine, zalcitabine, stavudine, lamivudine, emtricitabine, tenofovir disoproxil fumerate, abacavir, efavirenz, nevirapine, indinavir, saquinavir, ritonavir, nelfinavir, (fos)ampreavir, atazanavir and darunavir) and current use (zidovudine, didanosine, zalcitabine, lamivudine, stavudine, emtricitabine, tenofovir disoproxil fumerate and abacavir).
